ArticleSexually transmitted diseases2025
Relationship Between HSV-1 Serostatus and HSV-2 IgG Confirmation Results Using an Inhibition Assay.
Article in Sexually transmitted diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Herpes Simplex Virus Type 1 and Type 2 Western Blot Serology Test Results From 1999 to 2020 in a US Reference Laboratory.Sexually transmitted diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApproximately 2% of HerpeSelect herpes simples virus type 2 (HSV-2) IgG enzyme immunoassay (screen assay) sera-positive samples do not confirm using an HSV-2 IgG inhibition assay. Of these, roughly 1.33% are confirmed negative, and a small proportion (0.2%) are indeterminate due to inhibition observed with HSV-1 and HSV-2 lysate. The objective of this study was to assess the relationship between HSV-1 IgG serostatus and HSV-2 IgG confirmation results using the HSV-2 IgG inhibition assay.
methodsThis study included consecutive HSV-2 IgG screen-positive specimens regardless of index value. Specimens were also tested for HSV-1 IgG. The HSV-2 IgG confirmation results from the inhibition assay were evaluated to assess the relationship between inhibition results and HSV-1 serostatus.
resultsOf the 21,006 positive HSV-2 IgG specimens, 13,237 (63%) were also positive for HSV-1 IgG. The proportion of HSV-1 IgG-positive samples among inhibition-indeterminate samples (33 to 40 [83%]) was higher than among inhibition-negative (167 of 279 [60%]) and inhibition-positive (13,041 of 20,691 [63%]) samples. Among HSV-1 IgG-positive samples, the median HSV-1 IgG index was also significantly higher for the inhibition-indeterminate group (median, 48.8) than for the inhibition-negative (median, 30.7) and inhibition-positive groups (median, 31.2; P = 0.00013 and P = 3.1e - 05, respectively).
conclusionThese findings suggest that HSV-2 IgG inhibition-indeterminate, but not inhibition-negative, results are associated with higher index values of HSV-1 IgG. Further studies are needed to understand other factors associated with inhibition-indeterminate results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.